Voriconazole-d3
Based on 2 publication(s) in Google Scholar
Voriconazole-d3 is the deuterium labeled Voriconazole. Voriconazole (UK-109496) is a second-generation, broad-spectrum triazole antifungal agent that inhibits fungal ergosterol biosynthesis. Voriconazole exerts its antifungal activity by inhibition of 14-α-lanosterol demethylation, which is mediated by fungal cytochrome P450 enzymes.
For research use only. We do not sell to patients.
- Purity: 99.9%
- CAS No.: 1217661-14-7
- Formula: C16H11D3F3N5O
- Molecular Weight:352.33
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Voriconazole-d3
More
Biological Activity
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
1. This compound can be used as a tracer
2. This compound can be used as an internal standard for quantitative analysis by NMR, GC-MS, or LC-MS.
Chemical Information
-
CAS No. 1217661-14-7
-
Unlabeled Cas 137234-62-9
-
Appearance Solid
-
Molecular Weight 352.33
-
Formula C16H11D3F3N5O
-
Color White to off-white
-
SMILES
[2H]C([2H])([2H])[C@@H](C1=NC=NC=C1F)[C@@](O)(C2=C(C=C(C=C2)F)F)CN3C=NC=N3
-
Synonyms
UK-109496-d3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Drug Des Devel Ther
LC-MS/MS Method for Simultaneous Quantification of Three Oxazolidinone Antimicrobials in Human Plasma: Application to Therapeutic Drug Monitoring. [Abstract]2025 Oct 1:19:8903-8917. PMID: 41054619 -
Solvent & Solubility
DMSO : ≥ 50 mg/mL (141.91 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : 0.17 mg/mL (0.48 mM; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Purity & Documentation
-
Data Sheet (278 KB)
-
SDS (480 KB)
- English - EN (480 KB)
- Français - FR (480 KB)
- Deutsch - DE (480 KB)
- Norwegian - NO (480 KB)
- Español - ES (480 KB)
- Swedish - SV (480 KB)
- Italian - IT (480 KB)
- Korean - KR (480 KB)
- Portuguese - PT (480 KB)
-
Handling Instructions (2659 KB)
References
[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [Content Brief]
[2]. Nickie D Greer. Voriconazole: the newest triazole antifungal agent.Proc (Bayl Univ Med Cent). 2003 Apr;16(2):241-8. [Content Brief]
[3]. Lesley J Scott, et al. Voriconazole : a review of its use in the management of invasive fungal infections.Drugs. 2007;67(2):269-98. [Content Brief]
[4]. A M Sugar,et al. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis.Antimicrob Agents Chemother. 2001 Feb;45(2):601-4. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.8382 mL | 14.1912 mL | 28.3825 mL | 70.9562 mL |
| 5 mM | 0.5676 mL | 2.8382 mL | 5.6765 mL | 14.1912 mL | |
| 10 mM | 0.2838 mL | 1.4191 mL | 2.8382 mL | 7.0956 mL | |
| 15 mM | 0.1892 mL | 0.9461 mL | 1.8922 mL | 4.7304 mL | |
| 20 mM | 0.1419 mL | 0.7096 mL | 1.4191 mL | 3.5478 mL | |
| 25 mM | 0.1135 mL | 0.5676 mL | 1.1353 mL | 2.8382 mL | |
| 30 mM | 0.0946 mL | 0.4730 mL | 0.9461 mL | 2.3652 mL | |
| 40 mM | 0.0710 mL | 0.3548 mL | 0.7096 mL | 1.7739 mL | |
| 50 mM | 0.0568 mL | 0.2838 mL | 0.5676 mL | 1.4191 mL | |
| 60 mM | 0.0473 mL | 0.2365 mL | 0.4730 mL | 1.1826 mL | |
| 80 mM | 0.0355 mL | 0.1774 mL | 0.3548 mL | 0.8870 mL | |
| 100 mM | 0.0284 mL | 0.1419 mL | 0.2838 mL | 0.7096 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Voriconazole-d3 Related Classifications
HY-76200S Related Classifications
Powered by Bioz